226 results on '"Attard P"'
Search Results
52. Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America
53. Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer
54. MR-guided prostate SBRT in prostate cancer patients with low-volume metastatic disease
55. Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer
56. Genetic testing and management of prostate cancer patients with pathogenic germline variants
57. Validation of JSBMR’s CTIBL manual for Japanese men receiving androgen deprivation therapy for prostate cancer
58. Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US
59. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
60. Zielgerichtete Therapieoptionen in der Uroonkologie
61. Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis
62. Impact of COVID-19 on hospital screening, diagnosis and treatment activities among prostate and colorectal cancer patients in Canada
63. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
64. The Intersection of Prostate Cancer and Hypertension: a Call to Action
65. Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning
66. Deep learning algorithm-based multimodal MRI radiomics and pathomics data improve prediction of bone metastases in primary prostate cancer
67. Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression
68. Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
69. Potential role for protein kinase D inhibitors in prostate cancer
70. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer
71. Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus
72. The role of RNA modification in urological cancers: mechanisms and clinical potential
73. ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003
74. Development and validation of two nomograms for predicting overall survival and Cancer-specific survival in prostate cancer patients with bone metastases: a population-based study
75. Recent advances and future perspectives in the therapeutics of prostate cancer
76. The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance
77. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
78. Development and validation of a clinic machine-learning nomogram for the prediction of risk stratifications of prostate cancer based on functional subsets of peripheral lymphocyte
79. Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer
80. Symptoms and signs of urogenital cancer in primary care
81. Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis
82. Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
83. The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
84. Neoadjuvant Therapy for Locally Advanced or Oligometastatic Prostate Cancer: a Retrospective Comparative Single-Center Study
85. The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network
86. ImmunoPET for prostate cancer in the PSMA era: do we need other targets?
87. Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review
88. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer
89. Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer
90. Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
91. Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
92. The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+ prostate cancer cells by downregulating wnt, NF-κB and AKT signaling
93. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents
94. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection
95. Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study
96. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy
97. PSMA PET/CT and radiotherapy in prostate cancer: a winning team
98. YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
99. Multi-omics profiling of PC-3 cells reveals bufadienolides-induced lipid metabolic remodeling by regulating long-chain lipids synthesis and hydrolysis
100. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.